FibroGen Inc (NASDAQ:FGEN) Director Thomas F. Kearns, Jr. sold 18,000 shares of the company’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $23.17, for a total value of $417,060.00. Following the sale, the director now directly owns 161,464 shares of the company’s stock, valued at approximately $3,741,120.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

FGEN opened at $31.55 on Thursday. The company has a quick ratio of 6.77, a current ratio of 6.84 and a debt-to-equity ratio of 0.07. The stock’s 50 day moving average price is $38.89 and its two-hundred day moving average price is $40.73. The firm has a market capitalization of $2.78 billion, a P/E ratio of -32.86 and a beta of 1.77. FibroGen Inc has a 12-month low of $22.65 and a 12-month high of $55.71.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, March 2nd. The biopharmaceutical company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.53). FibroGen had a negative return on equity of 13.35% and a negative net margin of 30.00%. The business had revenue of $7.97 million for the quarter, compared to analyst estimates of $40.32 million. During the same quarter last year, the firm earned $0.23 earnings per share. The firm’s quarterly revenue was down 92.6% compared to the same quarter last year. As a group, analysts anticipate that FibroGen Inc will post -1.12 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the stock. Norges Bank acquired a new position in FibroGen during the 4th quarter valued at $32,156,000. FMR LLC increased its holdings in shares of FibroGen by 8.1% during the 4th quarter. FMR LLC now owns 9,434,188 shares of the biopharmaceutical company’s stock worth $404,632,000 after purchasing an additional 706,703 shares during the period. Farallon Capital Management LLC increased its holdings in shares of FibroGen by 35.0% during the 4th quarter. Farallon Capital Management LLC now owns 1,350,000 shares of the biopharmaceutical company’s stock worth $57,902,000 after purchasing an additional 350,000 shares during the period. Nuveen Asset Management LLC raised its position in shares of FibroGen by 46.4% during the fourth quarter. Nuveen Asset Management LLC now owns 749,657 shares of the biopharmaceutical company’s stock valued at $32,152,000 after buying an additional 237,655 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of FibroGen by 21.3% during the fourth quarter. Bank of New York Mellon Corp now owns 1,142,813 shares of the biopharmaceutical company’s stock valued at $49,016,000 after buying an additional 200,984 shares during the last quarter. 69.66% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have recently commented on the stock. Zacks Investment Research lowered shares of FibroGen from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 14th. BidaskClub downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a report on Wednesday, March 18th. Mizuho reiterated a “buy” rating and issued a $72.00 target price on shares of FibroGen in a research note on Thursday, February 13th. ValuEngine upgraded shares of FibroGen from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. Finally, Citigroup cut their target price on shares of FibroGen from $65.00 to $51.00 and set a “buy” rating for the company in a research report on Thursday, March 19th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. FibroGen has a consensus rating of “Hold” and a consensus target price of $51.20.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Featured Story: Diversification in Investing

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.